logo

For the Inventor, By the Inventor

Incheon, South Korea

Celltrion Inc.

USPTO Granted Patents = 36

% Expired Patents = 2.8



Trademarks = 62

Forward Citations = 52

Loading Chart...
Loading Chart...

151 inventors (with patents filed for the assignee):

goldMedal Shin Jae Chang (11 out of 11 patents)

silverMedal Su Jung Kim (6 out of 7 patents)

bronzeMedal Joon Won Lee (6 out of 6 patents)

4.  Won Yong Han (6 out of 6 patents)

5.  Jun Seok Oh (6 out of 6 patents)

6.  Yeon Kyeong Shin (6 out of 6 patents)

7.  Kye Sook Yi (6 out of 6 patents)

8.  So Young Kim (6 out of 45 patents)

9.  Kwang Woo Kim (5 out of 5 patents)

10.  Seung Suh Hong (5 out of 5 patents)

11.  Joo Hyuck Lim (4 out of 4 patents)

12.  Young Jun Park (4 out of 32 patents)

13.  Ki Sung Kwon (4 out of 6 patents)

14.  Hyun Joo Lee (4 out of 4 patents)

15.  Sung Ho Moon (3 out of 280 patents)


Core Competencies:
Immunogenic Composition
Pharmaceutical Composition
Binding Molecule
High Expression Protein
Stable Liquid Formulation
Nanostructure
Antibody Conjugate
Vaccine Composition
Recombinant Proteins
Cation Exchange Chromatography
Influenza Virus
Cosmetic Composition

36 patents:

1. 12758503 - Pharmaceutical formulation comprising cibenzoline or salt thereof (2026-10-13),
2. 12678494 - Immunogenic composition comprising multivalentpolysaccharide-protein conjugates (2026-07-14),
3. 12551465 - Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition (2026-02-17),
4. 12546779 - Binding molecule having neutralizing activity against SARS-coronavirus-2 (2026-02-10),
5. 12534738 - EXPRESSION CASSETTE INCLUDING INTRON FOR HIGH EXPRESSION OF PROTEIN OF INTEREST AND USE THEREOF (2026-01-27),
6. 12533343 - Method for preparing (−)-cibenzoline succinate (2026-01-27),
7. 12486237 - Polymorphic form of (-)-cibenzoline succinate (2025-12-02),
8. 12419863 - Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy (2025-09-23),
9. 12188036 - Expression cassette for production of high-expression and high-functionality target protein and use thereof (2025-01-07),
10. 12157764 - Dosing regimen for treating influenza virus diseases (2024-12-03),
11. 12065482 - Stable liquid pharmaceutical formulation of anti-influenza virus antibody (2024-08-20),
12. 11986523 - Stable liquid formula comprising anti-TNFa antibody, acetate buffer, and glycine (2024-05-21),
13. 11951207 - Stable liquid pharmaceutical preparation (2024-04-09),
14. 11730698 - Stable liquid pharmaceutical preparation (2023-08-22),
15. 11712407 - Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same (2023-08-01),
Company Overview
Celltrion Inc. is a biopharmaceutical company based in Incheon, South Korea, specializing in the development and manufacturing of biosimilars and novel therapeutics. The company focuses on innovative drug solutions for various diseases, including autoimmune disorders and cancer. With a commitment to advancing healthcare, Celltrion leverages cutting-edge biotechnology and extensive research capabilities to enhance patient outcomes globally. Its strategic emphasis on quality and efficacy positions it as a key player in the biopharmaceutical industry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Celltrion Inc. USPTO Patent Assignee Logo
36 Patents

#14 in Incheon, 402-040

#402 in South Korea

#18,745 in the World

Incheon, KR
Incheon, South Korea

Celltrion Inc.

Forward Citations = 52

151 inventors:

goldMedal Shin Jae Chang (11 out of 11 patents)

silverMedal Su Jung Kim (6 out of 7 patents)

bronzeMedal Joon Won Lee (6 out of 6 patents)

4.  Won Yong Han (6 out of 6 patents)

5.  Jun Seok Oh (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Celltrion Inc.. Retrieved from https://idiyas.com/company/celltrion

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…